Immunohistologic analysis of LMO2 protein expression in hematolymphoid neoplasia
| Lymphoma subtype . | Total positive* . | % positive . |
|---|---|---|
| B-cell lymphoma; n = 487 | ||
| Follicular lymphoma | 80/159 | 50 |
| Grade 1 | 16/41 | 39 |
| Grade 2 | 24/53 | 45 |
| Grade 3 | 40/65 | 62 |
| Diffuse large B-cell lymphoma | 92/197 | 47 |
| Mediastinal large B-cell lymphoma | 8/13 | 62 |
| Burkitt lymphoma | 5/10 | 50 |
| Extranodal marginal-zone lymphoma | 0/27 | 0 |
| Splenic marginal-zone lymphoma | 0/5 | 0 |
| Nodal marginal-zone lymphoma | 1/5 | 20 |
| Mantle-cell lymphoma | 0/18 | 0 |
| Small lymphocytic lymphoma/CLL | 0/36 | 0 |
| Lymphoplasmacytic lymphoma | 0/5 | 0 |
| Precursor B-lymphoblastic lymphoma | 5/12 | 42 |
| T-cell lymphoma; n = 138 | ||
| Precursor T-lymphoblastic lymphoma | 8/14 | 57 |
| Peripheral T-cell lymphoma | 0/25 | 0 |
| Anaplastic large-cell lymphoma | 0/8 | 0 |
| NK lymphoma | 5/91 | 5 |
| Plasma-cell neoplasms; n = 174 | ||
| Multiple myeloma | 3/153 | 2 |
| Plasma-cell leukemia | 0/13 | 0 |
| Monoclonal gammopathy | 0/8 | 0 |
| Hodgkin lymphoma; n = 122 | ||
| Lymphocyte predominant | 9/15 | 60 |
| Classical Hodgkin | 0/107 | 0 |
| Myeloid leukemia; n = 11 | ||
| Acute myeloid leukemia | 8/10 | 80 |
| Chronic myeloid leukemia | 1/1 | 100 |
| Lymphoma subtype . | Total positive* . | % positive . |
|---|---|---|
| B-cell lymphoma; n = 487 | ||
| Follicular lymphoma | 80/159 | 50 |
| Grade 1 | 16/41 | 39 |
| Grade 2 | 24/53 | 45 |
| Grade 3 | 40/65 | 62 |
| Diffuse large B-cell lymphoma | 92/197 | 47 |
| Mediastinal large B-cell lymphoma | 8/13 | 62 |
| Burkitt lymphoma | 5/10 | 50 |
| Extranodal marginal-zone lymphoma | 0/27 | 0 |
| Splenic marginal-zone lymphoma | 0/5 | 0 |
| Nodal marginal-zone lymphoma | 1/5 | 20 |
| Mantle-cell lymphoma | 0/18 | 0 |
| Small lymphocytic lymphoma/CLL | 0/36 | 0 |
| Lymphoplasmacytic lymphoma | 0/5 | 0 |
| Precursor B-lymphoblastic lymphoma | 5/12 | 42 |
| T-cell lymphoma; n = 138 | ||
| Precursor T-lymphoblastic lymphoma | 8/14 | 57 |
| Peripheral T-cell lymphoma | 0/25 | 0 |
| Anaplastic large-cell lymphoma | 0/8 | 0 |
| NK lymphoma | 5/91 | 5 |
| Plasma-cell neoplasms; n = 174 | ||
| Multiple myeloma | 3/153 | 2 |
| Plasma-cell leukemia | 0/13 | 0 |
| Monoclonal gammopathy | 0/8 | 0 |
| Hodgkin lymphoma; n = 122 | ||
| Lymphocyte predominant | 9/15 | 60 |
| Classical Hodgkin | 0/107 | 0 |
| Myeloid leukemia; n = 11 | ||
| Acute myeloid leukemia | 8/10 | 80 |
| Chronic myeloid leukemia | 1/1 | 100 |
LMO2 immunostaining was similar in intensity to normal germinal-center B cells and was localized to the nuclei in all hematopoietic neoplasms tested. Cases were scored positive if more than 30% of lymphoma cells stained for LMO2.